Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis by Roelofs, H. et al.
Restricted 12p Amplification and RAS Mutation in
Human Germ Cell Tumors of the Adult Testis
Helene Roelofs,* Marijke C. Mostert,*
Kirsten Pompe,*† Gaetano Zafarana,*
Monique van Oorschot,*
Ruud J. H. L. M. van Gurp,* Ad J. M. Gillis,*
Hans Stoop,* Berna Beverloo,‡
J. Wolter Oosterhuis,* Carsten Bokemeyer,† and
Leendert H. J. Looijenga*
From the Pathology/Laboratory for Experimental Patho-
Oncology,* University Hospital Rotterdam/Daniel, Josephine
Nefkens Institute, Rotterdam, The Netherlands; the Department of
Hematology and Oncology,† University of Tu¨bingen, Tu¨bingen,
Germany; and the Department of Cell Biology and Genetics,‡
Erasmus University Rotterdam, Rotterdam, The Netherlands
Human testicular germ-cell tumors of young adults
(TGCTs), both seminomas and nonseminomas, are
characterized by 12p overrepresentation, mostly as
isochromosomes, of which the biological and clinical
significance is still unclear. A limited number of
TGCTs has been identified with an additional high-
level amplification of a restricted region of 12p in-
cluding the K-RAS proto-oncogene. Here we show
that the incidence of these restricted 12p amplifica-
tions is ;8% in primary TGCTs. Within a single cell
formation of i(12p) and restricted 12p amplification
is mutually exclusive. The borders of the amplicons
cluster in short regions, and the amplicon was never
found in the adjacent carcinoma in situ cells. Semi-
nomas with the restricted 12p amplification virtually
lacked apoptosis and the tumor cells showed pro-
longed in vitro survival like seminoma cells with a
mutated RAS gene. However, no differences in prolif-
eration index between these different groups of sem-
inomas were found. Although patients with a semi-
noma containing a homogeneous restricted 12p
amplification presented at a significantly younger age
than those lacking it, the presence of a restricted 12p
amplification/RAS mutation did not predict the stage
of the disease at clinical presentation and the treat-
ment response of primary seminomas. In 55 primary
and metastatic tumors from 44 different patients who
failed cisplatinum-based chemotherapy, the re-
stricted 12p amplification and RAS mutations had the
same incidence as in the consecutive series of re-
sponding patients. These data support the model that
gain of 12p in TGCTs is related to invasive growth. It
allows tumor cells, in particular those showing char-
acteristics of early germ cells (ie, the seminoma
cells), to survive outside their specific microenviron-
ment. Overexpression of certain genes on 12p prob-
ably inhibits apoptosis in these tumor cells. However,
the copy numbers of the restricted amplification of
12p and K-RAS mutations do not predict response to
therapy and survival of the patients. (Am J Pathol
2000, 157:1155–1166)
Malignant transformation is a complex, multistep pro-
cess.1 Although involvement of several genes has been
suggested in the development of testicular germ-cell tu-
mors of young adults (TGCTs), histologically seminoma
and nonseminomas,2 evidence is lacking.
All TGCTs originate from carcinoma in situ (CIS).3,4 CIS
is frequently found in the parenchyma adjacent to an
invasive TGCT, being located on the inner side of the
basal membrane of the seminiferous tubules, in close
association with Sertoli cells.5 The mechanisms involved
in the development from CIS, via the microinvasive stage,
to overt invasive tumors are still unclear. Obviously tumor
cells are selected that are capable of surviving and grow-
ing outside of the specific microenvironment of the sem-
iniferous tubule.
The only consistent chromosomal anomaly in TGCTs is
the gain of the short arm of chromosome 12, mostly
because of isochromosomes of 12p.6,7 The copy number
of 12p reportedly predicts prognosis.8–10 K-RAS has
been proposed as the relevant gene on 12p,11–13 of
which the encoding protein (p21) is involved in signal
transduction. Mutated RAS has been found to be corre-
lated with poor prognosis in childhood acute lymphocytic
leukemia,14 and non-small-cell lung cancer.15,16 Re-
cently, activation of RAS has been shown to be involved
in tumor maintenance17,18 and in inducing anchorage-
independent growth because of inhibition of apopto-
sis.19,20 Indeed, a correlation between activated RAS and
metastatic capacity has been reported.21,22 Besides ac-
tivation by means of mutations, RAS can also be involved
in malignant transformation because of increased copy
numbers of the wild-type gene, resulting in overexpres-
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sion of wild-type mRNA and accumulation of the wild-
type protein.23–28
Seminomas are highly sensitive to irradiation and cis-
platinum-based chemotherapy. The vast majority of pa-
tients with metastatic nonseminomas is cured by cisplati-
num-based combination chemotherapy.29 Because the
clinical course of these tumors can still not be predicted
for individual patients, additional prognostic markers are
needed. Interestingly, activated RAS genes increase the
intrinsic resistance to radiation and cisplatinum thera-
py.30–34 It is unclear, however, whether amplification of
wild-type RAS has the same effect.
A small percentage of TGCTs has RAS mutations,35–37
of which the clinical relevance was not studied. We
showed previously that seminomas with a mutated RAS
gene have survival advantage in vitro and have reduced
apoptosis in the primary tumor.38,39 Noteworthy, in vitro
survival of tumor cells correlates with poor prognosis in
patients with metastatic TGCTs40 and adult acute my-
eloid leukemia.41 Recently, a number of invasive TGCTs
with amplification of a restricted region of 12p have been
identified.42–45 We showed that the shortest region of
overlap of amplification (SROA) is ;1.7 Mbases, contain-
ing three known genes, ie, SOX5, JAW1, and K-RAS.45 It
is unknown so far whether amplification of wild-type K-
RAS in these tumors has the same effects as RAS muta-
tions. Finally, the clinical relevance of a restricted 12p
amplification has not been conclusively investigated in
TGCTs.
The goal of this study is to further investigate the bio-
logical and clinical significance of gain of 12p sequences
in TGCTs. The incidence of restricted 12p amplification
was studied in a consecutive series of 76 untreated pri-
mary TGCTs. The newly found six tumors, as well as the
previously identified nine cases, were studied for the distri-
bution of the restricted 12p amplification within the tumor
(homogeneous or heterogeneous pattern), the borders of
the SROA, the presence of i(12p), the proliferative activ-
ity, the presence of apoptosis, and capacity of the tumor
cells to survive in vitro. In addition, corresponding CIS
and microinvasive seminoma were tested for the pres-
ence of the restricted 12p amplification. The clinical im-
portance of the restricted 12p amplification and RAS
mutation was further studied in 44 patients who failed
cisplatinum-based chemotherapy.
Materials and Methods
Samples
The freshly obtained tumor samples included in this study
were collected in close collaboration with urologists and
pathologists in the southwestern part of the Netherlands.
All tumors were obtained before chemotherapy and/or
irradiation. Directly after surgical removal, representative
parts of the tumor and adjacent normal tissue (when
available) were snap-frozen and other pieces were fixed
overnight in 10% buffered formalin and embedded in
paraffin. The sizes of the testis and the tumor were mea-
sured in three dimensions. The tumors were diagnosed
according to the World Health Organization classification
for testicular tumors.46 Nonseminomas containing both a
seminoma and a nonseminoma component were classi-
fied as combined tumors according to the British classi-
fication,47 instead of as nonseminomas according to the
World Health Organization classification system. Identifi-
cation of CIS, seminoma, and embryonal carcinoma was
aided by direct enzyme histochemical detection of alka-
line phosphatase activity on representative frozen tissue
sections, as reported before.48 The consecutive series
tested for the presence of a restricted 12p amplification
(see below) consisted of 46 seminomas, 23 nonsemino-
mas (14 embryonal carcinomas/yolk-sac tumors/terato-
mas; three teratomas; two embryonal carcinomas/yolk-
sac tumors; two yolk-sac tumors, one teratoma/yolk-sac
tumor; one embryonal carcinoma) and seven combined
tumors (three embryonal carcinomas/seminomas; three
embryonal carcinomas/yolk-sac/seminomas; one teratoma/
yolk-sac tumor/seminoma). The newly identified cases with
a restricted 12p amplification, and the previously found
cases45 and unpublished observations, were studied for
the borders of the amplicon (see below), the distribution
within the tumor (see below), presence of i(12p) by karyo-
typing (when available), proliferation index (see below), ap-
optosis, and in vitro survival, as described before (see be-
low).38,39 In addition, the formerly identified seminomas with
a mutated RAS gene37 were included in this analysis.
The analysis of the possible clinical impact of the re-
stricted 12p amplification/K-RAS mutation was studied on
a series of patients who failed cisplatinum-based chemo-
therapy. These cases were collected in collaboration with
the Departments of Hematology and Oncology, Univer-
sity of Tu¨bingen, Germany, and Internal Medicine, Neth-
erlands Cancer Institute, Amsterdam, The Netherlands.
In total, samples of 44 different patients were included, of
whom 22 primary TGCTs and 33 metastasis were studied
(of 11 patients both the primary and metastasis was
available).
Immunohistochemical Detection of Ki-67
Sections were cut from one representative paraffin block
per tumor, which was mounted on 3-aminopropyl-tri-
ethoxysilane-coated slides and dried at 50°C overnight.
Subsequently, the sections were heated to 120°C in so-
dium citrate solution (0.01 mol/L, pH 6.0) using an auto-
clave.49 Endogenous peroxidase reactivity was blocked
with H2O2/methanol. The Ki-67 antigen was demon-
strated using the polyclonal antibody A0047 (DAKO,
Glostrup, Denmark), diluted 1:100. Incubation was done
for 1 hour at room temperature after blocking of nonspe-
cific binding sites with 5% bovine serum albumin. After
extensive washing, biotinylated swine anti-rabbit (1:200)
(DAKO) was used as second step, which was detected
using the horseradish-labeled streptavidin-biotin com-
plex (DAKO) diluted 1:100. Peroxidase was visualized
with diaminobenzidine, after which the sections were
counterstained lightly with Mayer’s hemalum. Of each
tumor, 3 3 50 tumor cells were independently counted by
two observers in one tissue section. The results were
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statistically analyzed using the Student’s t-test. Positive
and negative (excluding the first antibody) controls were
included in each experiment.
Metaphase Preparations
After surgical removal representative parts of nonsemi-
nomas were enzymatically digested (collagenase; Sigma
Chemical Co., St. Louis, MO), and cultured in T75 flasks
(Corning Costar, Europe, Schiphol-Rijk, The Netherlands)
for several days under standard conditions, ie, 37°C in a
humidified atmosphere with 5% CO2 in air in Dulbecco’s
modified Eagle’s medium/HF12 culture medium with 10%
heat-inactivated fetal calf serum (Gibco-BRL, Life Tech-
nologies BV, Brueda, The Netherlands) as described
before.50 Mitotic cells were harvested after 2 to 4 hours of
colcemid treatment, swollen in hypotonic solution, and
fixed in methanol/acetic acid (3:1). Representative parts
of seminoma were directly processed to isolate meta-
phase spreads as described before.51 Briefly, the mitotic
cells were, after mechanical dissociation of the tumor,
directly harvested in the presence of colcemid. The cells
were subsequently swollen in hypotonic KCl/EGTA/
Hepes solution and fixed with methanol:acetic acid (3:1).
For conventional G-band karyotyping the air-dried prep-
arations were digested with pancreatin. The chromosome
constitution was described according to the International
System for Human Cytogenetic Nomenclature 1995.52
Restricted 12p Amplification
For the random screen the in situ hybridization experi-
ments on the methanol/acetic acid-fixed nuclei suspen-
sions on the consecutive series were performed as de-
scribed earlier45 using YAC#5 (mapped to 12p11.2–12.1;
kindly provided by Dr. B. Gemmill, Denver, CO). This
probe is known to map to the SROA as determined in our
earlier study.45 To make this probe suitable for the in situ
hybridization approach, it was purified by pulsed-field gel
electrophoresis, amplified, and labeled with digoxigenin-
11-dUTP (Roche Diagnostics Nedevland BV, Almeve,
The Netherlands) using a nick-translation kit (Gibco-
BRL). It was visualized with fluorescein isothiocyanate-
conjugated sheep-a-digoxigenin (Roche). The presence
of a 12p amplification was defined as reported before45
as being ;15 to 30 signals per interphase nucleus.
TGCTs identified with a restricted 12p amplification
were studied in more detail regarding the breakpoints
and distribution. Of these cases, frozen tissue sections of
16-mm thickness, containing tumor, microinvasive semi-
noma, and CIS (when available), were cut and air-dried
overnight at 37°C on microscope slides treated with
3-aminopropyl-triethoxysilane. In addition, one parallel
section (4-mm thickness) was stained with hematoxylin
and eosin (H&E) and the other for alkaline phosphatase
reactivity for histological examination. The slides for the
in situ hybridization were submerged in 70% ethanol
(220°C) for 1 hour and dehydrated in an increasing
ethanol series (80%, 90%, 100%, 2 minutes each) and
air-dried. Subsequently, the tissue sections underwent
protein digestion with 0.0005% pepsin (Sigma) in 0.01
mol/L HCl in water, 1 minute at 37°C, followed by a wash
step (phosphate-buffered saline, 5 minutes) and dehy-
dration. Hybridization was performed as described for
the methanol/acetic acid fixed nuclei.45 YAC#5 was used
as control probe in combination with another probe (test
probe) (Figure 1). In particular, probes positive for se-
quence-taq-sites D12S1945, D12S1688, and AFM267yc9
(on the distal side) and D12S1350E, KRAS2, D12S1313,
and D12S1411 (on the proximal border) were used as test
probes. YAC#5 was labeled as described above with
digoxigenin-11-dUTP, and visualized using fluorescein iso-
thiocyanate-conjugated sheep anti-digoxigenin (Roche).
The test probe was also labeled using nick-translation with
biotin-11-dUTP and detected using avidine-CY3 (Jackson
ImmunoResearch, West Grove, PA). A restricted 12p am-
plification was defined as the presence of nuclei with at
least 15 hybridization signals. The pattern was identified
as heterogeneous when the positive nuclei are scattered
throughout the tissue section: both regions with and with-
out restricted 12p amplification are present. In contrast,
the pattern is defined as homogeneous when all regions
showed tumor nuclei with restricted 12p amplification.
Because of tissue cutting artifacts, this does not exclude
the presence of single nuclei without such an amplifica-
tion. The criteria used to determine the borders of the
breakpoints was similar to that used in our former study.45
Briefly, the test probe was scored as part of the amplicon
when paired hybridization signals with the control probe
(YAC#5) was observed, and scored as outside the ampli-
con when less hybridization signals were found compared
to the control probe. Higher copy numbers of the test
probes (see above) compared to the control probe have not
been found so far.
The paraffin-embedded tissue sections of the treat-
ment-resistant TGCTs (4-mm thickness) were preincu-
bated overnight at 50°C, and subsequently baked for 10
minutes at 80°C. The sections were deparaffinized using
xylene, washed in 100% methanol four times at room
temperature, and air-dried. Sodium thiocyanate (1 mol/L)
pretreatment was done for 10 minutes at 80°C, after
which the slides were thoroughly rinsed in water. Diges-
tion was done using 8000 U pepsin (Sigma) in 0.2 mol/L
HCl in phosphate-buffered saline at 37°C for 30 to 40
minutes, depending on the tissue under investigation.
After rinsing in water at 4°C, dehydration was done using
a series of increasing ethanol concentrations (70%, 80%,
90%, and 100%). The hybridization with a K-RAS-specific
digoxigenin-labeled probe, washing, and detection pro-
cedures were performed as described for the methanol/
acetic acid-fixed nuclei (see above). A restricted 12p
amplification was defined as the presence of at least 10
hybridization signals of the K-RAS probe. Because of the
thickness of the tissue sections used, the tumors were not
scored for the presence of a homogeneous or heteroge-
neous pattern.
Visualization was done with a Zeiss Axioskop epifluo-
rescence microscope (Carl Zeiss, BV, Weesp, The Neth-
erlands) with a Pinkel filter in combination with a triple
band-pass filter, which enabled the observation of fluo-
rescein isothiocyanate, CY3, and DAPI in one view.
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Comparative Genomic Hybridization (CGH)
For CGH, metaphase spreads were prepared using stan-
dard procedures from in vitro phytohemagglutinin-stimu-
lated peripheral blood lymphocyte cultures of a healthy
male as reported previously.53 High molecular weight
DNA was isolated from the snap-frozen tissue samples
(test DNA) and from peripheral blood of a normal male
(reference DNA) using standard procedures.54 The CGH
procedure and analysis were performed as described
before.55 Both the control male DNA and the tumor DNA
were directly labeled by nick-translation with lissamine
and fluorescein isothiocyanate, respectively. The data
were analyzed using Quips XL software from Vysis
(Downers Grove, IL). Normalization was performed using
the average of the green-to-red fluorescent intensities for
the entire metaphase. At least 10 metaphases were stud-
ied for each case. Losses of DNA sequences were de-
fined as chromosomal regions where the average green-
to-red ratio and its 95% confidence intervals are below
0.9 whereas gains are .1.1.56 The heterochromatic
blocks of chromosomes 1, 9, 16, and Y, and the imme-
diate telomeric regions were excluded from the analysis
because these regions present variable results in exper-
iments with normal control DNAs.
Spectral Karyotyping
Spectral karyotyping was performed on a single semi-
noma with a restricted 12p amplification, demonstrated
both by CGH and in situ hybridization, using a spectral
karyotyping kit and analysis system (Vysis) with a slightly
modified procedure as described by the supplier. In
particular, proteinase K digestion was performed in 1
mol/L Tris-HCl, pH 7.5, and after denaturation of the
probe, the mix was kept on ice. Washing during the
detection procedure was performed in 55% formamide at
39°C instead of 45°C. In addition, 0.05% instead of 0.1%
Tween was used in 43 standard saline citrate, and the
last washing step was performed at room temperature.
RAS Gene Mutation Detection
Mutations in codon 12 or 13 of the N- and K-RAS gene were
analyzed by direct sequencing (Amplicycle; Amersham,
Figure 1. Schematic representation of the physical map of the 12p11.2-p12.1 region. Genes, STSs, and the position the YAC#5 probe (positive for STS D12S1057)
are indicated. The results of the double-fluorescent in situ hybridization experiments performed on frozen tissue sections to determine the shortest region of
overlap of amplification are shown. The continuous bold lines indicate the regions included in the restricted 12p amplification, and the dotted lines indicate
the regions outside the amplification. The probes specific for STSs D12S1945, D12S1688, AFM267yc9, K-RAS, D12S1313, and D12S1411 are used for these analyses.
The results are shown per histological subgroup (seminomas, nonseminomas, and combined tumors). The tumors studied in our previous analysis,45 are indicated
by an asterisk. Note that three breakpoints map between AFM267yc9 and D12S1688, and seven between AFM267yc9 and D12S1945 at the distal side, and six
between K-RAS and D12S1313 at the proximal side. The shortest region of amplification encompasses the genomic fragment between AFM267yc9 and K-RAS.
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Arlington Heights, IL), using primer NA (59-GACTGAGTA-
CAAACTGGTGG-39)/NB (59-CTCTATGGTGGGATCATATT-
39) and KA (59-GACTGAATATAAACTTGTGG-39)/KB (59-
CTATTGTTGGATCATATTCC-39), respectively, on DNA
isolated from snap-frozen seminomas tested for in vitro
survival and presence of apoptosis. DNA was isolated as
described above. Only histological areas containing
.70% tumor cells were used. In addition, the presence of
K-RAS codon 12 mutations was investigated in the series
of paraffin-embedded tumors of the nonresponding pa-
tients as follows: two 15-mm thickness sections from each
sample were first deparaffinized with xylene and then
dehydrated with absolute ethanol. A parallel section
(4-mm thickness) was stained with H&E to confirm the
presence of tumor and to check for histology. Only sec-
tions with a major tumor component were used for DNA
isolation. DNA was eluted in 30 ml of water by heating the
air-dried tissues at 95°C for 5 minutes. Typically 50 to 100
ng of DNA was used for each polymerase chain reaction
(PCR). Each sample was first tested with HLA-dQ prim-
ers57 to assess the quality of the eluted DNA. Only sam-
ples showing proper amplification were subsequently
used. The PCR reactions to detect mutations in codon 12
of K-RAS were performed essentially as described be-
fore58 with the following modifications. The K-RAS 59
primer used in the two rounds of amplifications carried a
biotin label at the 59 end. After the first MvaI digestion, the
PCR products were affinity purified on streptavidin-
coated paramagnetic beads (Dynal AS, Oslo, Norway)
and the bound PCR products were redigested on the
beads in 50 ml of MvaI buffer containing 10 U of enzyme
for 3 hours at 37°C. Subsequently the beads were affinity
purified and washed on the magnet to remove the buffer
and the unbound fraction. Finally, single-stranded DNA
was eluted from the bound fraction by boiling the beads
with 10 ml of water. One half of each fraction was used in
the second amplification step. Samples positive for mu-
tations in codon 12 were further characterized by cycle
sequencing the single-stranded DNA obtained by affinity
purification of the PCR products retained on the beads
after the final MvaI digestion. The procedure was con-
trolled at every stage with DNA samples obtained from
archival paraffin-embedded primary TGCTs with and
without codon 12 mutations.37
Detection of DNA Laddering
High molecular weight DNA was isolated from snap-
frozen histologically checked samples using standard
procedures (see above). DNA laddering was visualized
using ethidium bromide staining after electrophoresis of 1
mg as described previously.39
Results
Restricted 12p Amplification and i(12p) in
Primary Invasive TGCTs
The incidence of a restricted 12p amplification in primary
untreated TGCTs was determined by analysis of metha-
nol/acetic acid-fixed nuclei suspensions of 76 surgically
removed, consecutively collected TGCTs, including 46
seminomas, 23 nonseminomas, and seven combined tu-
mors (see Table 1 and Materials and Methods for histol-
ogy). Double-fluorescent in situ hybridization showed that
all tumor nuclei had more than four copies of 12p, and at
least three chromosome 12 centromeres (not shown). Six
tumors (7.9%), ie, four seminomas (8.7%), one nonsemi-
noma (4.3%), and one combined tumor (14.2%) showed
the restricted 12p amplification. So far, in total 15 primary
TGCTs with such a restricted 12p amplification are avail-
able (the six identified in this consecutive study and nine
previously found by us, of which six have been included
in our previous study45): nine seminomas, four nonsemi-
nomas, and two combined tumors. Karyotyping (Table 1)
revealed the presence of i(12p) in two of the six success-
fully analyzed seminomas with a restricted 12p amplifi-
cation. However, the presence of an i(12p) could not be
confirmed by in situ hybridization on matched metaphase
spreads, although the amplification was found (not
shown). Only one of the four karyotyped 12p amplifica-
tion-positive nonseminomas contained an i(12p) in some
of the metaphases studied, whereas the only karyotyped
combined tumor lacked it. Because of inappropriate
quality of this material no in situ hybridization could be
performed on these cases. In the informative cases, it
was found that the additional 12p sequences visualized
by in situ hybridization were predominantly (five of the
nine cases) present as tandemly organized units as add
Table 1. Results of Detection of the Restricted 12p Amplification Using Methanol/Acetic Acid-Fixed Nuclei Suspensions of a
Consecutive Series of Primary Seminomas, Nonseminomas, and Combined Tumors as Detected by Double-Fluorescent
In Situ Hybridization
Consecutive series i(12p) 1
HeterogeneityTested 112p amplification Karyotyping In situ hybridization
Seminoma 46 4 (9) 2/6 0/6 3/9
Nonseminoma 23 1 (4) 1/4 NA 4/4
Combined tumor 7 1 (2) 0/1 NA 2/2
Total 76 6 (15)
The total numbers of cases with a restricted 12p amplification identified so far are indicated between brackets. The results of karyotyping and in situ
hybridization on matched frozen tissue sections are also shown. Abbreviations: 112p amplification, with restricted 12p amplification; NA, not available.
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(12)(p11), add(p12), or add(p13), although other sites
were also found to contain 12p-specific sequences, in-
cluding parts of chromosomes 6, 8, and 11 (not shown).
Breakpoints Involved in the Restricted 12p
Amplification
In addition to our earlier report consisting of six cases,45
three seminomas, two nonseminomas, and one com-
bined tumor (indicated by an asterisk in Figure 1), in situ
hybridization was applied on the newly identified TGCTs
(n 5 9) with a restricted 12p amplification. Because this
analysis was done on frozen tissue sections instead of
methanol/acetic acid-fixed nuclei suspension, as in our
earlier study, all cases could be analyzed, including the
two previously identified noninformative cases.45 Again
YAC#5 was used in combination with probes specific for
the more proximal and distal regions of the contig (see
Figure 1 and Materials and Methods section). In accor-
dance with our previous findings, the amplified region
always includes the genomic fragment between STS
AFM267yc9 at the distal end and K-RAS at the proximal
end. Therefore, K-RAS, JAW1, and SOX5 are consistently
amplified in all TGCTs with a restricted 12p amplification,
irrespective of histology. In addition to this finding, the
borders of the amplicon appeared to cluster in narrow re-
gions: 40% between K-RAS and STS D12S1313 at the
proximal side (44.4% for seminoma and 25% for nonsemi-
noma), and 20% between AFM267yc9 and D12S1688 at
the distal side (11% for seminoma and 50% for nonsemi-
noma). In addition, 46.7% of the breakpoints map between
AFM267yc9 and D12S1945 (44.4% for seminoma and 75%
for nonseminoma) (Figure 1).
Intratumor 12p Amplification and Tumor
Heterogeneity
In situ hybridization results on the suspensions of nuclei
already indicated that the restricted 12p amplification
can be heterogeneously distributed in one tumor (not
shown). This was verified by in situ hybridization on frozen
tissue sections. Six out of the nine seminomas showed
the amplification homogeneously throughout the tumor
(Table 1). The other three cases showed regions with and
without amplification, of which two contained i(12p) by
karyotyping. All nonseminomas and combined tumors
showed a heterogeneous pattern. In two cases the am-
plification was present in a subpopulation of cells of the
yolk-sac tumor component, and in one in a subpopulation
of both the embryonal carcinoma and yolk-sac tumor
component. One of the combined tumors with the re-
stricted 12p amplification was a mixture of seminoma and
embryonal carcinoma. The amplification was found in a
subpopulation of both components. No i(12p) was iden-
tified in this case. The other combined tumor showed
amplification in a minority of the seminoma cells only and
karyotyping failed.
One of the nonseminomas, initially diagnosed as
mixed nonseminoma showed no i(12p) by karyotyping.
This tumor was xenografted (orthotopically into a nude
rat), and after ;10 months, a tumor completely com-
posed of yolk sac tumor was formed. Karyotyping after
direct harvesting revealed i(12p) in seven out of 14 meta-
phase spreads, confirmed by in situ hybridization (not
shown). These metaphase spreads did not contain the
12p amplification. However, a limited number of inter-
phase nuclei isolated from the original tumor and the
xenograft showed the presence of 12p amplification by
in situ hybridization (not shown). In situ hybridization on
frozen tissue sections of these tumors demonstrated that
,5% of the tumor cells from the primary tumor showed
the 12p amplification, preferentially in the embryonal car-
cinoma and yolk-sac tumor component. This percentage
was constant during subsequent xenograft passages.
CGH was performed on three seminomas with homo-
geneous restricted 12p amplification, three of the heter-
ogeneous nonseminomas, and on both combined tu-
mors. No other high-level amplifications, besides the one
on 12p, were found in these cases, and a similar pattern
of gains and losses was identified as reported before (not
shown).43,56 Every tumor with a restricted 12p amplifica-
tion also showed gain of the complete short arm of chro-
mosome 12, of which representative examples are illus-
trated in Figure 2A. Spectral karyotyping was done on
one seminoma, of which a sufficient number of meta-
phase spreads containing the restricted 12p amplifica-
tion was available. The results confirm the presence of
chromosome 12 material in the aberrant chromosome 12
derivatives and in the most telomeric region a part of
chromosome 20 (Figure 2B).
Restricted 12p Amplification and Tumor
Development
Matched CIS cells and microinvasive seminoma of the
TGCTs with 12p amplification were studied by in situ
hybridization on tissue sections. The cells of interest were
visualized by enzyme histochemistry for alkaline phos-
phatase reactivity. Out of the eight seminomas studied,
three showed the presence of both CIS and microinva-
sive seminoma, and one only of CIS. The amplification
was found in all microinvasive components, but never in
CIS (summarized in Table 2), of which examples are
shown in Figure 3. Also no restricted 12p amplification
was found in the matched CIS of one nonseminoma and
one combined tumor. The microinvasive seminoma cells
adjacent to the combined tumor showed also a hetero-
geneous pattern of restricted 12p amplification as de-
tected in the matched invasive tumor (not shown).
12p Amplification/RAS Mutation, Proliferation,
Apoptosis, and in Vitro Survival
Immunohistochemistry for ki-67 on histological sections
was performed to investigate the proliferation index in
seminomas containing 12p amplification (n 5 8) or RAS
mutation (n 5 4; of two no appropriate material was
available anymore), or neither of these (n 5 13). As
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indicated in Table 3, no differences between these
groups were observed. However, all nine seminomas
with 12p amplification, as well as five of the six with a
mutated RAS gene, demonstrated low levels of apoptosis
in the primary tumor, indicated by the lack of profound
DNA laddering after electrophoresis. In contrast, nine of
13 tested seminomas without any of these features
showed apoptosis (Table 3 and Figure 4).
The capacity of the tumor cells to survive in vitro after
disruption of their microenvironment to generate single
cell suspensions was studied as described before,38 of
which the results are also summarized in Table 3. We
excluded that one of the newly identified seminomas in
this study contained a mutation of either the N- or K-RAS
gene in codons 12 and 13 (not shown). All six seminomas
with a RAS mutation and all four tested seminomas with a
restricted 12p amplification showed prolonged in vitro
survival (at least up to 10 days). Eleven seminomas with-
out a restricted 12p amplification or RAS mutation of the
12 tested could not be maintained in vitro. Nine of these
showed profound apoptosis. The seminoma that showed
in vitro survival for several days did not show obvious
apoptosis.
The nonseminomas, with or without restricted 12p am-
plification all lacked significant apoptosis, as was found
for both combined tumors. All nonseminomas and one
combined tumor were successfully karyotyped after
short-term in vitro culturing, indicating that these tumors
allowed short-term culturing in vitro (see Materials and
Methods).
12p Amplification, RAS Mutation, and Clinical
Behavior
The age at clinical diagnosis of patients with a seminoma
with and without a restricted 12p amplification/RAS mu-
tation is indicated in Figure 5. No age differences exist
between seminoma and nonseminoma patients with and
without a RAS mutation (Figure 5 and not shown). Despite
the small number of cases, seminoma patients with a
restricted 12p amplification showed a trend toward a
younger age at clinical presentation than those without
(P 5 0.055, Student’s t-test). When only the seminomas
with a homogeneous pattern of 12p amplification were
included (n 5 6) (see above), the age difference was
significant: 36.7 years without a restricted 12p amplifica-
tion and 26.8 years with a restricted 12p amplification
(Figure 5; P 5 0.023, Student’s t-test). No differences
were found between these different groups regarding
stage of the disease (they all presented as stage I or II),
size of the tumor (see Table 3), and clinical response (all
had a complete response). In addition, no correlation was
found between outcome and age, stage, proliferation
Figure 2. A: Representative examples of CGH for chromosome 12 on two
seminomas without 12p amplification (left) and two with a homogeneous
restricted 12p amplification (right). Note that the seminomas with an am-
plification also show gain of the complete short arm of this chromosome. The
number of metaphase spreads analyzed is indicated. B: Representative ex-
ample of banding (left) and spectral karyotyping (real color at the right, and
false color in the middle) of a chromosome 12 derivative known to contain
restricted 12p amplification (as determined by in situ hybridization and
CGH). Note that the chromosome is composed of chromosome 12 material
(indicated in purple), except the most distal region of the p arm, showing
chromosome 20-specific material (indicated in blue).
Table 2. Summary of the Presence of the Restricted 12p
Amplification in the Different Development Stages
of Testicular Germ Cell Tumors of Young Adults,
as Determined by In Situ Hybridization on Frozen
Tissue Sections
Carcinoma
in situ
Micro-invasive
seminoma
Invasive
tumor
n 5 3 2 1 1 (SE)
n 5 1 2 NA 1 (SE)
n 5 1 2 NA 6 (NS)
n 5 1 2 6 6 (CT)
Abbreviations: SE, seminoma; NS, nonseminoma; CT, combined
tumor; NA, not available; 2, absence of restricted 12p amplification; 1,
presence of restricted 12p- amplification; 6, heterogeneous presence
of 12p amplification.
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Figure 3. Representative examples of double-fluorescent in situ hybridization on frozen tissue sections, 4-mm thick, using a probe specific for the centromeric
region of chromosome 12 (red), and YAC#5 (green), mapped within the shortest region of overlap of amplification (see Figure 1). Shown are carcinoma in situ
(A); microinvasive seminoma (B); and invasive seminoma (C) . The tumor cells are identified by the direct enzymatic alkaline phosphatase detection method
(stained in red) on a parallel tissue section.
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index, or apoptosis. Also no correlation was detected
between the presence of 12p amplification/RAS mutation
and proliferation index.
To extend the analysis of the clinical significance of
K-RAS mutations/12p amplifications, we retrospectively
investigated a series of 22 primary tumors and 33 surgi-
cal specimens from metastasis from a total of 44 different
patients who failed cisplatinum-based chemotherapy. No
K-RAS mutations were identified. The sensitive detection
method (see Materials and Methods), makes it highly
unlikely that mutated genes were obscured by a predom-
inance of wild-type alleles. A restricted 12p amplification
was detected once in a metastatic tumor (primary not
available).
Discussion
Although gain of the short arm of chromosome 12 has
already been recognized for more than 25 years as a
characteristic chromosomal anomaly in TGCTs,6,7 the
biological significance still remains unknown, and the
clinical importance is a matter of debate. Because over-
representation of 12p is found in all TGCTs,7,59 it is most
likely crucial in the development of this cancer. Here we
show that the actual incidence of a restricted 12p ampli-
fication is around 8% for primary TGCTs. Our earlier
observation that the three known genes JAW1, SOX5, and
K-RAS map in this region,45 is confirmed in the study
presented here. We hypothesized that if important genes
for the development of this cancer reside in this region of
12p, a comparative study of TGCTs with and without this
type of amplification could be meaningful. In addition,
because K-RAS maps within the SROA, these tumors
were compared with previously published seminomas
with a RAS mutation.37
Although we were unable to reduce the SROA, as
compared to our previous findings,45 it was found that the
breakpoints of the amplicon cluster in rather narrow re-
gions (40% between D12S1313 and K-RAS at the proxi-
mal end and 53% between AFM267yc9 and D12S1945 at
the distal end). Assuming that the STSs are spread over
the genome with intervals of ;250 kb, 160 fragments are
to be expected on the short arm of chromosome 12
(around 40 Mbases). The change that one breakpoint
maps within the region between STS AFM267yc and
D12S1945 is estimated to be three times 6.3E-3. The
change that six additional breakpoints map to that par-
ticular region is around 5.7E-9. In addition, the change
that six breakpoints map between K-RAS and D12S1313
is around 1.3E-11 (binomial distribution). This indicates a
Figure 4. Representative examples of the presence of DNA laddering after
electrophoresis (indicative for apoptosis) of 1-mg high molecular weight
DNA isolated from primary seminomas with and without a restricted 12p
amplification/RAS mutation. Note the correlation between less apoptosis and
the presence of a restricted 12p amplification or RAS mutation. In addition,
the results of in vitro culture of the tumor cells are shown (see also Table 3).
Figure 5. Schematical representation of the ages of patients at clinical pre-
sentation with a seminoma with and without 12p amplification and RAS
mutation (mean, average, and standard deviations are indicated). In addition,
the ages of the subgroup of patients with a homogeneous 12p amplification
are shown. No differences were found between the ages of patients with a
seminoma without either of these aberrations and those with a RAS mutation.
However, those with a 12p amplification-positive seminoma showed a bor-
derline significant difference compared to the control group, whereas a
significant difference was found in case only patients with a homogeneous
12p amplification were included (P 5 0.023). Abbreviations: RAS1, RAS
mutation; RAS2/12p2, no RAS mutation or 12p amplification; 12p1, 12p
amplification both heterogeneously and homogeneously present; 12p1
homo, homogeneous 12p amplification.
Table 3. Summary of the Results on Proliferation Index, Apoptosis, In Vitro Survival, and Volume of the Tumor (cm3) in
Seminomas With and Without a Restricted 12p Amplification/RAS Mutation
Wild-type RAS Mutant RAS
Proliferation
index
Apoptosis
In vitro
survival Tumor
volume
Proliferation
index
Apoptosis
In vitro
survival Tumor
volume1 2 1 2 1 2 1 2
12p-ampl.
2 34.5 (10.5) 9 4 1 11 256 (173) 30.8 (3.1) 1 5 6 0 121 (88)
1 29.7 (15.3) 0 9 4 0 246 (294) NA NA NA NA NA NA
Abbreviations: 12p-ampl., restricted 12p amplification; 1, present; 2, absent; NA, not available. Standard deviations are indicated between
brackets.
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strong positive selection toward these particular regions.
Because no fragile sites have been identified at these
regions, the closest fragile site has been reported on
12p11,60 which might be related to the development of
the isochromosome 12p, the borders may be determined
by the presence of genes which confer selective advan-
tage to the tumors. If this is true, the amplicon contains at
least two genes of interest, a hypothesis that is currently
under investigation.
All TGCTs with 12p amplification identified so far also
show gain of the complete short arm of chromosome 12.
Interestingly, seminomas with a homogeneous 12p am-
plification, ie, present in all cells, lack i(12p), whereas
those showing a heterogeneous pattern could contain an
isochromosome. The restricted 12p amplification and
i(12p) were never found in the same cell. A similar pattern
was found for the nonseminomas and combined tumors.
Interestingly, the seminomatous components of the com-
bined tumors showed a similar pattern of restricted 12p
amplification as the pure seminomas. Clearly, 12p ampli-
fication is found predominantly in TGCTs without i(12p).
These results suggest that there are at least two mecha-
nisms leading to extra copies of the short arm of chro-
mosome 12 in TGCTs: i(12p) formation, and an alterna-
tive way, also leading to extra copies of the complete
short arm of chromosome 12, which can be followed by
amplification of a restricted region of 12p.
The homogeneous presence of 12p amplification in
most of the identified seminomas (and not in nonsemino-
mas) implies that increased copy numbers of genes
present in the amplified region result in a selective ad-
vantage for these tumor cells containing this specific
anomaly. We demonstrated that this is related to a re-
duced apoptosis and not because of enhanced prolifer-
ation. A similar lack of apoptosis was observed previ-
ously by us in seminomas containing a mutated RAS
gene,38,61 which also showed an enhanced in vitro sur-
vival and reduced apoptosis. These results are in accor-
dance with the idea that activation of RAS by mutation or
amplification can cause inhibition of apoptosis.
Despite data on the role of activated RAS in resistance
to irradiation and chemotherapy and induction of meta-
static potential21,22,30–34 and our results on in vitro sur-
vival and apoptosis,38,39 no differences were found re-
garding stage of the primary seminoma at clinical
presentation and treatment response based on the pres-
ence of a RAS mutation or restricted 12p amplification.
This is supported by an observation in two patients:62 the
restricted 12p amplification (detected by CGH) was
present in both a responding and a nonresponding tumor.
In addition, we observed no predictive value of K-RAS mu-
tations and restricted 12p amplification in chemoresistance
of patients with extensively pretreated TGCTs. Patients hav-
ing a seminoma with a homogeneous restricted 12p ampli-
fication were, however, younger at clinical presentation than
those lacking it. This is most likely explained by an early
development of the restricted 12p amplification in these
tumors, leading to reduced apoptosis. This combined with
an unchanged proliferation index results in faster growth of
the tumor and an earlier clinical presentation. Such an age
difference was not observed in the case of a RAS mutation,
which is likely because mutation of RAS is a relatively late
event in the pathogenesis of TGCTs. This is supported by
our observation that TGCTs with a mutated RAS gene also
show gain of the complete short arm of chromosome 12,
although no information about the presence of i(12p) is
available (not shown).
Our data suggest that RAS mutation and restricted 12p
amplification are related to invasive growth of TGCTs. It
allows tumors cells to survive outside the specific micro-
environment of the CIS cells by inhibition of induction of
apoptosis, known as “anoikis.”20 The reason that homo-
geneous 12p amplification is predominantly found in
seminomas can be related to the diminished requirements
of nonseminomatous tumor cells for survival. This idea is
supported by the relative ease of short-term culture for
karyotyping,59 and the success rate of establishing non-
seminoma cell lines.63 It remains to be established whether
involvement of RAS causes down-regulation of FAS, as
suggested recently,64,65 and whether activation of the
serine/threonine kinase AKT is involved.66,67 In addition, it is
unknown thus far which genes in the SROA are in fact
involved. The absence or at least lower incidence of gain of
12p sequences in CIS as reported before68–70 and unpub-
lished observations support this model.
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